First Human Trials for Recombinant Dengue Fever Vaccine
Phase one clinical trials to start for Dengue Fever Vaccine program
Acuvax CEO and Hawaii Biotech Inc Director, Dr William Ardrey said: “We are pleased to deliver on our guidance to the market that the recombinant vaccine will be trialled in humans in the USA this quarter.”
According to the company, Hawaii Biotech’s Dengue monovalent vaccine candidate is the first recombinant subunit vaccine for dengue to enter clinical studies. Hawaii Biotech intends to test a dengue tetravalent vaccine candidate, developed using the company’s recombinant subunit vaccine technology, within a year. Hawaii Biotech’s dengue subunit vaccine candidate has been developed with financial assistance from the National Institutes of Health, the Department of Defence, and the Paediatric Dengue Vaccine Initiative (which is funded by the Bill & Melinda Gates Foundation).
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous